For the quarter ending 2025-09-30, ALLO has $439,771K in assets. $124,442K in debts. $37,815K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 37,815 | 52,332 | ||
| Short-term investments | 214,379 | 220,788 | ||
| Prepaid expenses and other current assets | 8,525 | 9,535 | ||
| Total current assets | 260,719 | 282,655 | ||
| Long-term investments | 24,944 | 29,510 | ||
| Operating lease right-of-use asset | 40,935 | 41,966 | ||
| Property and equipment, net | 75,896 | 78,858 | ||
| Deposit placed in escrow | 23,472 | 23,484 | ||
| Restricted cash | 10,292 | 10,292 | ||
| Other long-term assets | 3,513 | 3,828 | ||
| Total assets | 439,771 | 470,593 | ||
| Accounts payable | 3,699 | 4,851 | ||
| Accrued and other current liabilities | 28,134 | 26,824 | ||
| Total current liabilities | 31,833 | 31,675 | ||
| Lease liability, noncurrent | 77,134 | 79,241 | ||
| Other long-term liabilities | 15,475 | 15,116 | ||
| Total liabilities | 124,442 | 126,032 | ||
| Common stock, 0.001 par value 400,000,000 shares authorized as of september30, 2025 and december 31, 2024 223,163,672 and 212,210,597 shares issued and outstanding as of september30, 2025 and december 31, 2024, respectively | 223 | 220 | ||
| Additional paid-in capital | 2,286,770 | 2,274,885 | ||
| Accumulated deficit | -1,971,899 | -1,930,499 | ||
| Accumulated other comprehensive loss | 235 | -45 | ||
| Total stockholders equity | 315,329 | 344,561 | ||
| Total liabilities and stockholders equity | 439,771 | 470,593 | ||
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)